The joint effects of different types of glucose-lowering treatment and duration of diabetes on total and cardiovascular mortality among subjects with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 82, Issue 1, 2008, Pages 139-147

  Khalangot, Mykola ^a   Tronko, Mykola ^a   Kravchenko, Victor ^a   Kulchinska, Jaroslava ^a   Hu, Gang ^b,c  

^a V P Komisarenko Institute of Endocrinology and Metabolism of the Ukraine Academy of Medical Sciences   (Ukraine)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Duration of diabetes; Mortality; Treatment; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING HABIT; TREATMENT OUTCOME; UKRAINE;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; UKRAINE;

EID: 52949123588     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.07.002     Document Type: Article

References (38)

1. Hu G., Jousilahti P., Qiao Q., Katoh S., and Tuomilehto J. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia 48 (2005) 856-861
2. Hu G., Sarti C., Jousilahti P., Qiao Q., Antikainen R., and Tuomilehto J. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke 36 (2005) 2538-2543
3. Hu G., Jousilahti P., and Tuomilehto J. Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur. Heart J. 28 (2007) 3059-3066
4. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002) 2570-2581
5. Waller B.F., Palumbo P.J., Lie J.T., and Roberts W.C. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years, analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am. J. Med. 69 (1980) 498-506
6. Vigorita V.J., Moore G.W., and Hutchins G.M. Absence of correlation between coronary arterial atherosclerosis and severity or duration of diabetes mellitus of adult onset. Am. J. Cardiol. 46 (1980) 535-542
7. Cho E., Rimm E.B., Stampfer M.J., Willett W.C., and Hu F.B. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J. Am. Coll. Cardiol. 40 (2002) 954-960
8. Hu F.B., Stampfer M.J., Solomon C.G., Liu S., Willett W.C., Speizer F.E., et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch. Intern. Med. 161 (2001) 1717-1723
9. Spijkerman A.M., Dekker J.M., Nijpels G., Jager A., Kostense P.J., van Hinsbergh V.W., et al. Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study. Eur. J. Clin. Invest. 32 (2002) 924-930
10. Fox C.S., Sullivan L., D'Agostino Sr. R.B., and Wilson P.W. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diab. Care 27 (2004) 704-708
11. Bo S., Ciccone G., Gancia R., et al. Mortality within the first 10 years of the disease in type 2 diabetic patients. Nutr. Metab. Cardiovasc. Dis. 16 (2006) 8-12
12. Morrish N.J., Stevens L.K., Head J., Fuller J.H., Jarrett R.J., and Keen H. A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics). II. Associated risk factors. Diabetologia 33 (1990) 542-548
13. Uusitupa M.I., Niskanen L.K., Siitonen O., Voutilainen E., and Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36 (1993) 1175-1184
14. Johnson J.A., Majumdar S.R., Simpson S.H., and Toth E.L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diab. Care 25 (2002) 2244-2248
15. Evans J.M., Ogston S.A., Emslie-Smith A., and Morris A.D. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49 (2006) 930-936
16. de Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., and Muggeo M. Cause-specific mortality in type 2 diabetes: the Verona Diabetes Study. Diab. Care 22 (1999) 756-761
17. DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia 46 (2003) 608-617
18. Gu K., Cowie C.C., and Harris M.I. Diabetes and decline in heart disease mortality in US adults. JAMA 281 (1999) 1291-1297
19. Gregg E.W., Gu Q., Cheng Y.J., Narayan K.M., and Cowie C.C. Mortality trends in men and women with diabetes 1971-2000. Ann. Intern. Med. (2007)
20. Tronko N., Khalangot N., Kravchenko V., Kul'chinskaia B., Gur'ianov V., and Mis'ko L. Incidence of proliferative retinopathy and sex-related differences in death rate among patients with diabetes mellitus and sight impairment treated with insulin according to the data from national diabetic registry. Lik. Sprava (2004) 29-32
21. Khalangot M., and Tronko M. Primary care diabetes in Ukraine. Prim. Care Diab. 1 (2007) 203-205
22. Cox D.R. Regression models and life tables (with discussion). J. R. Stat. Soc. B 34 (1972) 187-220
23. Brun E., Nelson R.G., Bennett P.H., Imperatore G., Zoppini G., Verlato G., et al. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diab. Care 23 (2000) 1119-1123
24. Fuller J.H., Stevens L.K., and Wang S.L. Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes. Diabetologia 44 Suppl. 2 (2001) S54-S64
25. Natarajan S., Liao Y., Sinha D., Cao G., McGee D.L., and Lipsitz S.R. Sex differences in the effect of diabetes duration on coronary heart disease mortality. Arch. Intern. Med. 165 (2005) 430-435
26. Hu G. DECODE Study Group, Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia 46 (2003) 608-617
27. Hu G., Jousilahti P., Qiao Q., Peltonen M., Katoh S., and Tuomilehto J. The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. J. Am. Coll. Cardiol. 45 (2005) 1413-1418
28. Meinert C.L., Knatterud G.L., Prout T.E., and Klimt C.R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19 Suppl. (1970) 789-830
29. Cornfield J. The University Group Diabetes Program, a further statistical analysis of the mortality findings. JAMA 217 (1971) 1676-1687
30. Schor S. The University Group Diabetes Program, a statistician looks at the mortality results. JAMA 217 (1971) 1671-1675
31. Seltzer H.S. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 21 (1972) 976-979
32. UK Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
33. Simpson S.H., Majumdar S.R., Tsuyuki R.T., Eurich D.T., and Johnson J.A. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174 (2006) 169-174
34. Hill A.B. The environment and disease: association or causation?. Proc. R. Soc. Med. 58 (1965) 295-300
35. Sackett D.L., Shannon H.S., and Browman G.W. Fenoterol and fatal asthma. Lancet 335 (1990) 45-46
36. Meier J.J., Gallwitz B., Schmidt W.E., Mugge A., and Nauck M.A. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. Heart 90 (2004) 9-12
37. Knuiman M.W., Welborn T.A., and Whittall D.E. An analysis of excess mortality rates for persons with non-insulin-dependent diabetes mellitus in Western Australia using the Cox proportional hazards regression model. Am. J. Epidemiol. 135 (1992) 638-648
38. Khalangot M. Current practice of insulin and oral hypoglycaemic agents treatment of diabetes mellitus type 2 patients according to diabetes mellitus register data analysis in the city of Donetsk, Ukraine. Prim. Care Diab. 1 (2007) 224